Synonym
Doxaminol; BM10188; BM-10188; BM 10188
IUPAC/Chemical Name
2-Propanol, 1-((2-(6,11-dihydrodibenz(b,e)oxepin-11-yl)ethyl)methylamino)-3-phenoxy-
InChi Key
SZQLTQPHXXXMNC-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H29NO3/c1-27(17-21(28)19-29-22-10-3-2-4-11-22)16-15-24-23-12-6-5-9-20(23)18-30-26-14-8-7-13-25(24)26/h2-14,21,24,28H,15-19H2,1H3
SMILES Code
OC(COC1=CC=CC=C1)CN(CCC2C3=CC=CC=C3OCC4=CC=CC=C24)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
403.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Neidlein R, Volland C, Kramer W. Spektroskopische Eigenschaften des partiellen beta-agonisten Doxaminol (BM 10.188) und seiner Stoffwechselprodukte [Spectroscopic properties of the partial beta-agonist doxaminol (BM 10.188) and its metabolites]. Arch Pharm (Weinheim). 1990 May;323(5):259-65. German. doi: 10.1002/ardp.19903230503. PMID: 2383170.
2: Neidlein R, Volland C, Strein K. Biotransformation of the partial beta- agonist doxaminol in dog. Arzneimittelforschung. 1990 Feb;40(2 Pt 1):130-6. PMID: 1970733.
3: Neidlein R, Volland C, Strein K. Pharmacokinetics of the partial beta-agonist doxaminol in dog. Arzneimittelforschung. 1990 Jan;40(1):27-31. PMID: 2339996.
4: Sterz H, Sponer G, Neubert P, Hebold G. A postulated mechanism of beta- sympathomimetic induction of rib and limb anomalies in rat fetuses. Teratology. 1985 Jun;31(3):401-12. doi: 10.1002/tera.1420310311. PMID: 2861668.
5: Sponer G, Schaumann W. Increase in the cardiotonic action and in the therapeutic margin of digoxin by the adrenergic beta-stimulant doxaminol in cats. Arzneimittelforschung. 1985;35(11):1663-7. PMID: 3004517.
6: Haass M, Sponer G, Abshagen U. Arrhythmogenic dose of acetylstrophanthidin unchanged by beta-sympathomimetics in conscious dogs. Basic Res Cardiol. 1984 Nov-Dec;79(6):679-89. doi: 10.1007/BF01908385. PMID: 6152394.
7: Bödigheimer K, Ischinger T, Nowak FG, Delius W. Positiv-inotrope Akuteffekte von Doxaminol bei Herzinsuffizienz [Positive inotropic effects of doxaminol in congestive heart failure]. Z Kardiol. 1983 Jan;72(1):48-52. German. PMID: 6837086.
8: Whiting B, Kelman AW, Sumner DJ, Hillis WS, Ledermann H. Haemodynamic effects of BM 10.188, a new orally active inotropic agent, in healthy volunteers. Br J Clin Pharmacol. 1982 Apr;13(4):529-32. doi: 10.1111/j.1365-2125.1982.tb01416.x. PMID: 7066168; PMCID: PMC1402041.
